Abstract: The present invention provides a Ganoderma lucidum ?-glucan extract, a preparation method and detection method therefor. The preparation method includes: S1: crushing fruiting bodies of Ganoderma lucidum, mixing the crushed fruiting bodies with a solvent, adding trypsin for enzymatic hydrolysis for 0.5-2 h, and separating to obtain a Ganoderma lucidum fruiting body filter residue; S2: mixing the Ganoderma lucidum fruiting body filter residue with an alkali solution, carrying out ultrasonic extraction with heating, adjusting the pH value of the obtained filtrate to be neutral, and concentrating to obtain a crude Ganoderma lucidum polysaccharide; S3: carrying out alcohol precipitation on the crude Ganoderma lucidum polysaccharide, separating the obtained precipitate, and freeze-drying to obtain a crude Ganoderma lucidum ?-glucan extract; and S4: purifying the crude Ganoderma lucidum ?-glucan extract by glucose gel column chromatography to obtain a Ganoderma lucidum ?-glucan extract.

Abstract: The invention provides a preparation method of high-content Ganoderma lucidum ?-glucan and an efficient and rapid detection method thereof. The preparation method comprises ethanol-trypsin pretreatment of Ganoderma lucidum fruiting body in combination with ultrasonic-assisted alkaline hydrothermal extraction of ?-glucan from Ganoderma lucidum, and purifying ?-glucan by DEAE Sephadex A-25 Sephadex column chromatography using NAOH solution as a mobile phase, to obtain high purity (?90%) of Ganoderma lucidum ?-glucan. The detection method comprises placing the extracted ?-glucan in an autoclave and performing hydrolysis with ?-(1,3)-exo-glucanase and ?-glucosidase, and detecting and analyzing the content of the prepared ?-glucan by high pressure-acid enzymatic hydrolysis-HPLC method, using glucose as a standard. The preparation method of ?-glucan has high extraction ratio.

Abstract: A fingerprint spectrum construction method for a new compound aloe capsule and a fingerprint spectrum includes: (1) taking powder of a new compound aloe capsule, carrying out reflux extraction, adding methanol, carrying out ultrasonic treatment, filtering, and taking a subsequent filtrate as a test solution; dissolving barbaloin, aloe-emodin, indirubin, tryptanthrin, aloesin, and ?-sitosterol in methanol to obtain reference solutions; (2) injecting the test solution and the reference solutions into a high performance liquid chromatograph for gradient elution to obtain a chromatogram of the new compound aloe capsule and chromatograms of the reference solutions, respectively; and (3) labeling chemical components of peaks on the chromatogram of the new compound aloe capsule according to the chromatogram of the new compound aloe capsule and the chromatograms of the reference solutions to obtain a fingerprint spectrum of the new compound aloe capsule.

Abstract: A fingerprint spectrum construction method for Xihuang capsules and a fingerprint spectrum includes: S1: taking contents of a Xihuang capsule, adding a methanol-chloroform-phosphoric acid solution, and carrying out ultrasonic extraction to obtain a Xihuang capsule test solution; S2: dissolving cholic acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, muscone, and myrrhone in ethanol to obtain a mixed standard solution 1; dissolving quassin, 11-carbonyl-?-boswellic acid, 11-carbonyl-?-acetyl-boswellic acid, acetyl-11?-methoxy-?-boswellic acid, and sandaracopimaric acid in methanol to obtain a mixed standard solution 2; S3: respectively carrying out chromatography on the Xihuang capsule test solution and the mixed standard solutions 1 and 2, and recording corresponding chromatograms; and S4: constructing a fingerprint spectrum of the Xihuang capsule according to the chromatogram of the Xihuang capsule test solution and the chromatograms of the mixed standard solutions 1 and 2.

Abstract: The present invention relates to application of gossypol and its optical isomers to preparation of an anti-Coronavirus drug. Specifically disclosed is application of pharmaceutically acceptable salts, solvates, isotopes, stereoisomers, stereoisomer mixtures, and tautomers of the gossypol and its optical isomers to preparation of a drug for preventing and/or treating a disease caused by a Coronavirus. The Coronavirus is MERS-CoV, SARS-CoV, or SARS-CoV-2. It is found in the present invention for the first time that the gossypol and its optical isomers can inhibit the activity of Coronavirus 3CL proteases to achieve an anti-Coronavirus effect. The half maximal inhibitory concentrations of gossypol and (?)-gossypol to SARS-CoV proteases and SARS-CoV-2 3CL proteases are all lower than 10 ?M. The anti-Coronavirus 3CL protease effect is good. Therefore, the gossypol and its optical isomers have the potential for use in the preparation of a drug for preventing and/or treating novel Coronavirus infections.

Abstract: A pleuromutilin cinnamic acid ester compound with activities against antibiotic-resistant infections having the following formula (I) R1, R2, R3, R4 and R5 are independently hydrogen, halogen, nitro, cyano, methoxy, trifluoromethyl, benzyloxy, aryl or dimethylamino.

Abstract: The present invention relates to the technical field of medicinal chemistry, and particularly to a method for preparing a 3-tetrazolylmethyl-1,3,5-triazin-2,4-dione compound inhibiting coronavirus 3CL protease activity and use thereof. Specifically, a compound of Formula I, or a pharmaceutically acceptable salt, or an optical isomer, or an isotope-substituted form thereof is provided. The compound effectively inhibits the SARS-CoV-2 3CLpro activity, and is useful in the preparation of a SARS-CoV-2 3CLpro inhibitor to block the replication and transcription of SARS-CoV-2 viruses in patients. The compound prepared in the present invention has high in-vitro safety, and very good prospect of application in the preparation of SARS-CoV-2 3CLpro inhibitors and anti-SARS-CoV-2 drugs.

Abstract: A Syringa microphylla seed extract includes the following components by weight based on a total weight of the Syringa microphylla seed extract: 0.4944-0.7142 mg/g of echinacoside, 6.624-7.617 mg/g of oleuropein, 0.4276-0.6309 mg/g of verbascoside, 3.927-4.684 mg/g of syringin, and 4.505-5.250 mg/g of forsythiaside B. A method of preparing the Syringa microphylla seed extract is disclosed. A composition for treating antibiotic-resistant infections that includes the Syringa microphylla seed extract is also disclosed.

Abstract: A pleuromutilin cinnamic acid ester compound with activities against antibiotic-resistant infections having the following formula (I) R1, R2, R3, R4 and R5 are independently hydrogen, halogen, nitro, cyano, methoxy, trifluoromethyl, benzyloxy, aryl or dimethylamino.

Abstract: A method of preparing a hydroxytyrosol sturgeon skin gelatin film with antioxidant activity and Salmonella detection ability includes: (1) mixing a neutral red indicator solution and distilled water at room temperature to obtain a mixture solution, and adding 1 mol/L NaHCO3 solution to the mixture solution until discoloration to obtain an alkaline solution; (2) adding an amount of the alkaline solution obtained in step (1) to a mixture of Sturgeon skin gelatin and distilled water to obtain an alkaline gelatin solution; (3) adding hydroxytyrosol and glycerin and propylene glycol to the alkaline gelatin solution to obtain a hydroxytyrosol gelatin solution, and heating the hydroxytyrosol gelatin solution at 40-70° C.; (4) ultrasonicating the hydroxytyrosol gelatin solution from step (3), placing the hydroxytyrol gelatin solution evenly on a clean plexiglass plate, drying the hydroxytyrol gelatin solution on an ultra-clean worktable to obtain the hydroxytyrosol sturgeon skin gelatin film.

Abstract: Disclosed is a compound of formula I, a pharmaceutically acceptable salt, or a tautomer thereof. formula I. R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, methyl group, tert-butyl group, methoxy group, difluoromethyl, trifluoromethyl, trifluoromethoxy, nitro, halogen, phenyl and aromatic heterocyclic; R5 is a hydrogen or halogen; and R6 is hydrogen, C1-4 alkane or C1-4 cycloalkane.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.

Abstract: A method of preparing a Polygoni Milletii Rhizome tincture includes: preparing a first mixture; extracting the first mixture with 70-90% ethanol under reflux condition to obtain a first extract solution; preparing a second mixture; extracting the second mixture with 50-70% ethanol to obtain a second extract solution; and mixing the first extract solution with the second extract solution to obtain the polygoni milletii rhizome tincture. A method of preparing a Polygoni Milletii Rhizome poultice includes: reparing a Polygoni Milletii Rhizome mixture; mixing the Polygoni Milletii Rhizome mixture and a skin penetration enhancer in water; mixing a moisturizing agent and a binder in water; adding a thickener in water; mixing methylparaben and ethylparaben in 90% ethanol; mixing all solutions to form a mixture; and applying the mixture on a non-woven fabric cloth and drying to form the Polygoni Milletii Rhizome poultice.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound of formula I or formula II, a pharmaceutically acceptable salt, or a tautomer thereof is disclosed. The Linker is or and n is 1-6.

Abstract: A compound of formula I or formula II, a pharmaceutically acceptable salt, or a tautomer thereof is disclosed. In formula I and II, n is 1-6.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the formula (I): (I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.